<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SPECTINOMYCIN HYDROCHLORIDE</span><br/>(spek-ti-noe-mye'sin)<br/><span class="topboxtradename">Trobicin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>400 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Antibiotic produced by <i>Streptomyces spectabilis.</i> Action is usually bacteriostatic. Variable activity against a wide variety of gram-negative and gram-positive organisms.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits majority of <i>Neisseria gonorrhoeae</i> strains; effective for urethral and anorectal infections, but not pharyngeal. Not active against syphilis or chlamydial and
         mycoplasmal infections.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Only for treatment of uncomplicated gonorrhea in patients sensitized or resistant to penicillin or other effective drugs approved
         by US Centers for Disease Control and Prevention.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Disseminated gonococcal infections caused by penicillinase-producing strains of <i>N. gonorrhoeae</i> (PPNG) and sexually transmitted epididymoorchitis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safety during pregnancy (category B), lactation, and in infants and children <img src="../images/special/lesserorequal.gif"/>8
         y is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of allergies.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Uncomplicated Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 2 g as single dose<br/><span class="rdage">Child:</span> <span class="rdroute">IM</span>
<i> 40 mg/kg (max: 2 g); <i>&gt;45 kg,</i> use adult dosing<br/><br/><span class="indicationtitle">Disseminated Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 2 g q12h for 7 d or until switched to oral medication<br/><span class="rdage">Child:</span> <span class="rdroute">IM</span>
<i><img src="../images/special/greaterorequal.gif"/>8 y and</i>
<i><img src="../images/special/greaterorequal.gif"/>45 kg,</i> 2 g q12h for 7 d<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give IM injection deep into upper outer quadrant of gluteus. No more than 5 mL should be injected into single site (using
            20-gauge needle). Injection may be painful.
         </li>
<li>Reconstitute with supplied diluent (bacteriostatic water for injection with 0.9% benzyl alcohol). Shake vial vigorously
            immediately after adding diluent and before withdrawing drug.
         </li>
<li>Use solution within 24 h of reconstitution.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span>
<span class="speceff-common">Pain and soreness at injection site,</span> urticaria, pruritus, transient rash. <span class="typehead">Body as a Whole:</span> Headache, dizziness, chills, fever, insomnia, nervousness. <span class="typehead">GI:</span> Nausea, vomiting. <span class="typehead">Metabolic:</span> Decrease in Hgb, Hct, Cl<sub>cr</sub>, elevated serum alkaline phosphatase, ALT, BUN. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from IM site. <span class="typehead">Peak:</span> 1 hr. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1.22.8 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Observe patient for 4560 min after injection. Systemic anaphylaxis has been reported (apprehension, pruritus, hypertension,
            abdominal pain, collapse).
         </li>
<li>Obtain serologic tests for syphilis at time of diagnosis in patients with gonorrhea and again after 3 mo.</li>
<li>Monitor clinical effectiveness of drug to detect antibiotic resistance.</li>
<li>Culture all gonococcal infection sites 37 d after spectinomycin therapy is completed to verify eradication of infection.</li>
<li>Lab tests: Monitor Hgb and Hct when multiple doses are required.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify sexual partners of their risk of infection.</li>
<li>Refrain from sexual intercourse until infection is resolved.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>